NEW YORK (GenomeWeb News) – Fisher Scientific will exclusively distribute Response Biomedical's RAMP cardiac products in Canada under a deal announced today.
Financial and other terms of the agreement were not disclosed.
Fisher Scientific is part of Thermo Fisher Scientific.
According to Vancouver, British Columbia-based Response Biomedical, point-of-care testing in Canada is projected to reach C$63 million ($66.2 million) this year with an estimated growth rate of 7 percent over the next few years.
Response Bio's RAMP system consists of a reader and single-use disposable test cartridges. RAMP clinical tests are commercially available for the early detection of heart attack and congestive heart failure.